THE COURSE OF CARDIOVASCULAR COMPLICATIONS IN PATIENTS WITH COVID-19
Main Article Content
Abstract
In a pandemic situation caused by a coronavirus infection, a special risk group is made up of patients with cardiovascular diseases, which are often found in the population. The co-occurrence of these diseases increases the risk of adverse effects. Caring for these patients requires physicians to be aware of the characteristics of the viral infection, its clinical presentation, the events that occur in association with cardiovascular disease, and individual and collective protection measures. The safety of medical personnel and a good prognosis for patients is one of the highest values of the modern healthcare system. Arrhythmias , myocarditis and heart failure are not only typical clinical manifestations of coronavirus infection, but also occupy a prominent place in the structure of mortality. The problem is exacerbated by the potential cardiotoxicity and arrhythmogenicity of a number of drugs prescribed for the treatment of COVID-19. All this requires maximum cardiac vigilance in the treatment of patients with COVID-19, timely use of echocardiography, ECG, control of biomarkers of myocardial damage and stress, as well as pathogenetically justified prescription of cardiotonic and cardioprotective drugs.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
Aghagoli G., Gallo MB, Soliman LB et al. Cardiac involvement in COVID-19 patients: Risk factors, predictors, and complications: A review // J. Card. Surg. ‒ 2020. ‒ Apr 19. DOI: 10.1111/jocs.14538. .
Alhobani T. Acute myocarditis associated with novel Middle east respiratory syndrome coronavirus // Ann. Saudi Med. ‒ 2016. ‒ Vol. 36, No. 1. ‒ P. 78–80. doi: 10.5144/0256‒4947.2016.78.
Chen C., Zhou Y., Wang DW SARS-CoV-2: a potential novel etiology of fulminant myocarditis // Herz. ‒ 2020. ‒ Vol. 45, No. 3. - P. 230-232. DOI: 10.1007/s00059-020-04909-z.
Driggin E., Madhavan MV, Bikdeli B. et al. Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic // J. Am. Coll. cardiol. ‒ 2020. ‒ Vol. 75, No. 18. - P. 2352‒2371. doi: 10.1016/j.jacc.2020.03.031.
Ferrario CM, Jessup J., Chappell MC et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2 // Circulation. ‒ 2005. ‒ Vol. 111, No. 20. ‒ P. 2605‒2610. DOI: 10.1161/CIRCULATIONAHA.104.510461.
Gaddi AV, Galuppo P., Yang J. Creatine phosphate administration in cell energy impairment conditions: a summary of past and present research // Heart. lung. Circ. ‒ 2017. ‒ Vol. 26, No. 10. ‒ P. 1026‒1035. DOI: 10.1016/j. hlc.2016.12.020.
Guo T., Fan Y., Chen M. et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19) // JAMA Cardiol. ‒ 2020. ‒ Vol. 27. ‒ R. e201017. DOI: 10.1001/jamacardio.2020.1017.
Gurwitz D. Angiotensin receptor blokers as tentative SARS-CoV-2 // Therapeutic Drug. dev. Res. ‒ 2020. ‒ Mar 4; 10.1002/ddr.21656. DOI: 10.1002/ddr.21656. URL: researchgate.net
Huang C., Wang Y., Li X. et al. С linical features of patients infected with 2019 novel coronavirus in Wuhan, China // Lancet. ‒ 2020. ‒ Vol. 395. - P. 497-506. DOI: 10.1016/S0140-6736(20)30183-5.
Inciardi RM, Lupi L., Zaccone G. et al. Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19) // JAMA Cardiol. ‒ 2020. ‒ Mar 27. doi: 10.1001/jamacardio.2020.1096.
Kochi AN, Tagliari AP, Forleo GB et al. Cardiac and arrhythmic complications in patients with COVID-19 // J. Cardiovasc. Electrophysiol. ‒ 2020. ‒ Vol. 31, No. 5. ‒ P. 1003‒1008. DOI: 10.1111/jce.14479.
Long B., Brady WJ, Koyfman A. et al. Cardiovascular complications in COVID-19 // Am. J. Emerg. Med. ‒ 2020. ‒ Apr 18. ‒ P. 1‒4. DOI: 10.1016/j. ajem.2020.04.048.
Mehra MR, Desai SS, Ruschitzka F. et al. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis // Lancet. ‒ 2020. ‒ Published Online May 22. DOI: https://doi. org/10.1016/S0140-6736(20)31180-6.
Niu L., An XJ, Tian J. et al. 124 cases of clinical analysis of children with viral myocarditis. Eur. Rev. Med. Pharmacol. Sc., 2015, vol. 19, no. 15, pp. 2856‒2859. PMID: 26241540.
Oudit GY, Kassiri Z., Jiang C. et al. SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS // Eur. J.Clin. Invest. ‒ 2009. ‒ Vol. 39, No. 7. - P. 618-25. doi: 10.1111/j.1365‒2362.2009.02153.x.
Shi S., Qin M., Shen B. et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China // JAMA Cardiol. ‒ 2020. ‒ Vol. 25. ‒ R. e200950. DOI: 10.1001/jamacardio.2020.0950.
Williams B., Zhang Y. Hypertension, rennin-angiotensin-aldosterone system inhibition, and COVID-19 // Lancet. ‒ 2020. ‒ May 18. DOI:10.1016/s0140-6736(20)31131-4.
Xu Z., Shi L., Wang Y. et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome // Lancet Respir. Med. ‒ 2020. ‒ Vol. 8, No. 4. ‒ P. 420–422. doi: 10.1016/S2213-2600(20)30076-X.
Yang C., Jin Z. An acute respiratory infection runs into the most common noncommunicable epidemic ‒ COVID-19 and Cardiovascular Diseases // JAMA Cardiol. ‒ 2020. ‒ Vol. 25. doi: 10.1001/jamacardio.2020.0934.
Yu CM, Wong RS, Wu EB et al. Cardiovascular complications of severe acute respiratory syndrome // Postgrad. Med. J. - 2006. - Vol. 82 (964). ‒ P. 140‒144. DOI: 10.1136/pgmj.2005.037515.
Zeng J., Huang J., Pan L. How to balance acute myocardial infarction and COVID-19: the protocols from Sichuan Provincial People's Hospital // Intens. Care Med. ‒ 2020. ‒ Vol. 11. - P. 1 - 3. DOI: 10.1007/s00134-020-05993-9.
Zhou F., Yu T., Du R. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study // Lancet. ‒ 2020. ‒ Vol. 395 (10229). ‒ P. 1054‒1062. doi: 10.1016/S0140-6736(20)30566-3.
Zhu H., Rhee JW, Cheng P. et al. Cardiovascular complications in patients with COVID-19: consequences of viral toxicities and host immune response // Curr. cardiol. Rep. ‒ 2020. ‒ Vol. 22, No. 5. ‒ P. 32. DOI: 10.1007/s11886-020-01292-3.
Avdeikin S. N., Tyurin I. N., Kozlov I. A. Correction of hemodynamics in severe community-acquired pneumonia complicated by acute respiratory distress syndrome // Medical Alphabet. ‒ 2018. ‒ V. 2, No. 18. ‒ P. 19–28.
Anesthesiological and resuscitation support for patients with a new coronavirus infection COVID-19: Guidelines. Official website of the Federation of Anesthesiologists and Resuscitators http://www. far.org.ru/recommendation.
Bautin A. E., Osovskikh V. V. Acute right ventricular failure // Bulletin of anesthesiology and resuscitation. ‒ 2018. ‒ V. 15, No. 5. ‒ P. 74–86. DOI: https://doi.org/10.21292/2078-5658-2018-15-5-74-86.
Belova Yu. N., Tarasova A. A., Ostreikov I. F. Efficacy of cardiotrophic therapy in newborns with posthypoxic myocardial injury // General Reanimatology. ‒ 2011. ‒ V. 7, No. 4. ‒ P. 38–42. DOI: https://doi.org/10.15360/1813-9779-2011-4-38.
Eremenko A. A. Drug treatment of acute heart failure: what is and what awaits us // Bulletin of anesthesiology and resuscitation. ‒ 2020. ‒ V. 17, No. 2. ‒ P. 29‒37. DOI: 10.21292/2078-5658-2020-17-2-29-37.
Lomivorotov VV, Lomivorotov VN Perioperative injury and myocardial infarction // Bulletin of anesthesiology and resuscitation. ‒ 2019. ‒ V. 16, No. 2. ‒ P. 51–56. DOI: 10.21292/2078-5658-2019-16-2-51-56.
Abdurakhmanovich , K.O. , & ugli , G.S.O. (2022). Ultrasound Diagnosis of the Norm and Diseases of the Cervix. CENTRAL ASIAN JOURNAL OF MEDICAL AND NATURAL SCIENCES, 3(2), 58-63. Retrieved from https://cajmns. centralasianstudies. org/index.php/CAJMNS/article/view/622
Abdurakhmanovich , K.O. , & ugli , G.S.O. (2022). Ultrasonic Diagnosis Methods for Choledocholithiasis. CENTRAL ASIAN JOURNAL OF MEDICAL AND NATURAL SCIENCES , 3 (2), 43-47. Retrieved from https://cajmns. centralasianstudies. org/index.php/ CAJMNS/article/view/619